ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

9:00AM-11:00AM: Abstract Number: 1548

Blood Pressure, BMI and Sex Affect Optical Spectral Transmission Imaging Measurements of the Hands

Imaging of Rheumatic Diseases Poster

9:00AM-11:00AM: Abstract Number: 1755

Body Mass Index Trajectory and Variability in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1590

Bone Health in ANCA – Associated Vasculitis Patients

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1747

Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebo-controlled Trial (PreCePRA)

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Abstract Number: 1575

CD6 Is a Target for Cancer Immunotherapy

Immunological Complications of Therapy Poster

9:00AM-11:00AM: Abstract Number: 1621

Cervical Cancer Screening Among Women with Systemic Lupus Erythematosus or Prescribed Tumor Necrosis Alpha-inhibitors Who Receive Outpatient Rheumatology Care

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1550

Change in Tophus Size Measured with Dual-energy CT and Ultrasound: A 1-year Multicenter Follow-up Study

Imaging of Rheumatic Diseases Poster

9:00AM-11:00AM: Abstract Number: 1817

Changes in Macular Capillary Network Measured with Optical Coherence Tomography-angiography in Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1531

Characterization of Cytokine/chemokine Profile in Patient-derived M1/ M2 Macrophages to Identify Biomarkers for Genetically-defined Systemic Autoinflammatory Diseases

Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1945

Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1558

Cinematic Rendering Enables Depiction of Bone Anabolic Effects in Patients Treated with Baricitinib

Imaging of Rheumatic Diseases Poster

9:00AM-11:00AM: Abstract Number: 1901

Clinical Characteristics of Importance to Outcome in Patients with Axial Spondyloarthritis: A Prospective Cohort Study

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

9:00AM-11:00AM: Abstract Number: 1572

Clinical Characteristics of Methotrexate Associated Lymphoproliferative Disorders and RA Treatment After Lymphoproliferative Onset in 92 Cases

Immunological Complications of Therapy Poster

9:00AM-11:00AM: Abstract Number: 1904

Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

9:00AM-11:00AM: Abstract Number: 1863

Clinical History as Tool for Diagnosis and Classification of Patients with Ankylosing Spondylitis (Axial Spondyloarthritis): Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

«Previous Page
1
…
3
4
5
6
7
…
36
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].